A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2013
At a glance
- Drugs Dovitinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Oct 2011 Actual Number of Patients is 60 added as reported by ClinicalTrials.gov.
- 24 Oct 2011 Planned End Date changed from 1 Sep 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.